947249-41-4

Usage

Uses

Used in Organic Synthesis:
6-Aminopyrazine-2-boronic acid pinacol ester is used as a reagent in the synthesis of various pharmaceutical and agrochemical compounds. Its pinacol ester moiety and boronic acid group contribute to its utility in cross-coupling reactions, making it a key component in the development of new and innovative molecules.
Used in Cross-Coupling Reactions:
In the field of organic chemistry, 6-aminopyrazine-2-boronic acid pinacol ester is utilized as a building block for cross-coupling reactions. Its pinacol ester functionality facilitates these reactions, enabling the formation of new carbon-carbon bonds and the synthesis of complex organic molecules.
Used in Suzuki-Miyaura Coupling Reactions:
6-Aminopyrazine-2-boronic acid pinacol ester is employed in Suzuki-Miyaura coupling reactions, a type of cross-coupling reaction used to form carbon-carbon bonds. Its boronic acid group plays a crucial role in this process, allowing for the efficient formation of new molecular structures.
Used in Biological Imaging Applications:
6-Aminopyrazine-2-boronic acid pinacol ester has been explored for its potential as a fluorescent probe in biological imaging. Its unique properties make it a candidate for use in visualizing and studying biological processes at the molecular level, contributing to advancements in both research and diagnostics.
Used in Research and Industry:
6-Aminopyrazine-2-boronic acid pinacol ester is a versatile compound with applications in both research and industry. Its diverse uses in organic synthesis, cross-coupling reactions, and biological imaging make it an important tool for scientists and professionals in various fields.

Upstream product

• 73183-34-3 bis(pinacol)diborane 
• 59489-71-3 5-amino-2-bromopyrazine 

Downstream Products

• 1313026-84-4 5-(9-benzyl-2-chloro-9H-purin-6-yl)-pyrazin-2-yl-amine 

Relevant academic research and scientific papers

A Conformational Restriction Strategy for the Identification of a Highly Selective Pyrimido-pyrrolo-oxazine mTOR Inhibitor

The mechanistic target of rapamycin (mTOR) plays a pivotal role in growth and tumor progression and is an attractive target for cancer treatment. ATP-competitive mTOR kinase inhibitors (TORKi) have the potential to overcome limitations of rapamycin derivatives in a wide range of malignancies. Herein, we exploit a conformational restriction approach to explore a novel chemical space for the generation of TORKi. Structure-activity relationship (SAR) studies led to the identification of compound 12b with a ～450-fold selectivity for mTOR over class I PI3K isoforms. Pharmacokinetic studies in male Sprague Dawley rats highlighted a good exposure after oral dosing and a minimum brain penetration. CYP450 reactive phenotyping pointed out the high metabolic stability of 12b. These results identify the tricyclic pyrimido-pyrrolo-oxazine moiety as a novel scaffold for the development of highly selective mTOR inhibitors for cancer treatment.

Small molecule compound

The invention provides a small molecular compound, The small molecular compound is characterized by having a structure as shown in the following molecular general formula, wherein X1 and X2 are selected from carbon or nitrogen, G1 is a carbon ring or a heterocyclic ring with aromaticity, any one or more hydrogen atoms on the G1 ring are substituted by R1, wherein R1 is selected from nitrogen-containing groups. The small molecule compound can be used as an efficient and specific JAK kinase inhibitor, especially a Tyk2 inhibitor, and/or a JAK1 inhibitor, and/or a JAK1/Tyk2 dual inhibitor, or a Tyk2/JAK1 dual inhibitor or a Tyk2/Jak2 dual inhibitor.

Efficient synthesis of pyrazine boronic esters via palladium-catalyzed Miyaura borylation

A facile and efficient protocol for palladium-catalyzed Miyaura borylation reaction of chloropyrazines with B2pin2has been developed. A certain range of difficult-to-access pyrazine boronic esters can be easily prepared from the corresponding chloropyrazines in moderate to good yields.

Aminoheteroaryl benzamides as kinase inhibitors

The present invention provides a compound of Formula (I) or a salt thereof; and therapeutic uses of these compounds. The present invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds with a therapeutic co-agent.

Synthesis and in vitro and in vivo evaluation of phosphoinositide-3-kinase inhibitors

Phospoinositide-3-kinases (PI3K) are important oncology targets due to the deregulation of this signaling pathway in a wide variety of human cancers. A series of 2-morpholino, 4-substituted, 6-(3-hydroxyphenyl) pyrimidines have been reported as potent inh